Hospitalizations for COPD Exacerbations: Trends and Determinants of Death.
Nicolas Molinari, Camille Briand, Isabelle Vachier...
https://pubmed.ncbi.nlm.nih.gov/26263032Actively Recruiting
Age: 18Years +
All Genders
ID05704881
Monitoring of the End-tidal Carbon Dioxide (EtCO2) as a Severity Criterion in COPD Exacerbations: a Prospective Observational Study
Led by University Hospital, Grenoble · Updated on 2026-04-15
240
Participants Needed
2
Research Sites
13 weeks
Total Duration
On this page
Sponsors
U
University Hospital, Grenoble
Lead Sponsor
H
Hospices Civils de Lyon
Collaborating Sponsor
AI-Summary
What this Trial Is About
Chronic obstructive pulmonary disease (COPD) is a common and serious lung condition affecting 8 to 12% of adults and is a leading cause of death in developed countries. This research investigates the use of end-tidal carbon dioxide (EtCO2), a non-invasive measurement, to predict severe COPD exacerbations and estimate arterial carbon dioxide levels without the need for blood sampling. Early detection of exacerbations is important to improve patient survival. In this observational study conducted in emergency departments, patients admitted with acute COPD exacerbations will have their EtCO2 levels measured by nurses using a mask or oxygen glasses at the time of initial assessment. Treatment will follow current international guidelines, and the doctors will not see the EtCO2 results. Researchers will then track whether patients require invasive or non-invasive ventilation within the first 24 hours after admission. Participants will be monitored during their emergency department stay, with clinical data collected from medical records 24 hours after admission. Additional measures include arterial blood gas tests taken about 15 minutes after arrival to compare EtCO2 readings with blood carbon dioxide levels. The study focuses on how well EtCO2 predicts the need for ventilation support and its agreement with standard blood gas measurements, helping to improve assessment and treatment of COPD flare-ups.
CONDITIONS
Brief Title
Monitoring of the End-tidal Carbon Dioxide (EtCO2) as a Severity Criterion in COPD Exacerbations
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
- Patient presenting to the emergency department with acute shortness of breath and a documented or reported history of COPD
- Male or female aged 18 years or older
- Did not oppose participation in the study
You will not qualify if you...
- Low blood pressure (systolic below 90 mmHg or mean below 65 mmHg)
- Previously included in the study during an earlier emergency visit
- Already receiving invasive or non-invasive ventilation upon emergency admission
- COPD exacerbation ruled out after medical and additional examinations
- Non-communicative, non-French speaking, impaired comprehension, or impaired consciousness
- Protected persons under French public health code articles L1121-6 and L1121-8 (deprived of liberty, under tutorship or curatorship)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person) at emergency department reception
Diagnostic Evaluation
Duration - Within 15 minutes after emergency admission
Participants undergo measurement of end-tidal carbon dioxide (EtCO2) during vital sign assessment at emergency department reception using a mask or oxygen glasses. Additional arterial blood gas measurements occur shortly after admission.
1 visit (in-person) at emergency department
Long-term Monitoring
Duration - 24 hours after admission
Participants are observed after discharge from the emergency department with clinical outcomes collected 24 hours after admission from medical records.
No additional visits; data collected from medical records
Trial Site Locations
Total: 2 locations
1
CHU Grenoble Alpes
Grenoble, Isère, France, 38000
Actively Recruiting
2
Hospices Civils de Lyon
Lyon, Rhône, France, 69000
Actively Recruiting
Loading map...
Research Team
N
Nicolas SEGOND, MD
P
Prudence MABIALA MAKELE, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Relationship between end-tidal carbon dioxide and arterial carbon dioxide in critically ill patients on mechanical ventilation: A cross-sectional study.
Jinrong Wang, Jianjun Zhang, Yajing Liu...
https://pubmed.ncbi.nlm.nih.gov/34414969The value of ETCO2 measurement for COPD patients in the emergency department.
Mutlu Kartal, Erkan Goksu, Oktay Eray...
https://pubmed.ncbi.nlm.nih.gov/20224417Capnography monitoring in nonintubated patients with respiratory distress.
Patricia Jabre, Line Jacob, Harold Auger...
https://pubmed.ncbi.nlm.nih.gov/19931750The accuracy of mainstream end-tidal carbon dioxide levels to predict the severity of chronic obstructive pulmonary disease exacerbations presented to the ED.
Nurettin Özgür Doğan, Alp Şener, Gül Pamukçu Günaydın...
https://pubmed.ncbi.nlm.nih.gov/24560835Correlation of PaCO2 and ETCO2 in COPD Patients with Exacerbation on Mechanical Ventilation.
Diksha Tyagi, Manjunath B Govindagoudar, Sushmitha Jakka...
https://pubmed.ncbi.nlm.nih.gov/33790512Guidelines for the Content of Statistical Analysis Plans in Clinical Trials.
Carrol Gamble, Ashma Krishan, Deborah Stocken...
https://pubmed.ncbi.nlm.nih.gov/29260229STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies.
Patrick M Bossuyt, Johannes B Reitsma, David E Bruns...
https://pubmed.ncbi.nlm.nih.gov/26511519A concordance correlation coefficient to evaluate reproducibility.
L I Lin
https://pubmed.ncbi.nlm.nih.gov/2720055